Exogenous Delta9-tetrahydrocannabinol influences circulating endogenous cannabinoids in humans

Journal of Clinical Psychopharmacology

Volumn 33, Issue 5, 2013, Pages 699-705

  Walter, Carmen ^a   Ferreirós, Nerea ^a   Bishay, Philipp ^a   Geisslinger, Gerd ^a   Tegeder, Irmgard ^a   Lötsch, Jörn ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ANANDAMIDE; CANNABINOID RECEPTOR; DRONABINOL; ENDOCANNABINOID; N OLEOYLETHANOLAMINE; PLACEBO; BENZOXAZINE DERIVATIVE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CNR1 PROTEIN, RAT; CNR2 PROTEIN, RAT; MORPHOLINE DERIVATIVE; NAPHTHALENE DERIVATIVE; PSYCHOTROPIC AGENT;

ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DORSAL ROOT; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG METABOLISM; FEMALE; HUMAN; HUMAN EXPERIMENT; HYPOTHALAMUS; MALE; NONHUMAN; NORMAL HUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAT; REGULATORY MECHANISM; SINGLE DRUG DOSE; SOMATOSENSORY CORTEX; SOMATOSENSORY STIMULATION; SPINAL CORD; ANIMAL; BLOOD; BRAIN; DRUG EFFECTS; GERMANY; LEWIS RAT; METABOLISM; ORAL DRUG ADMINISTRATION; TIME; UPREGULATION; CONTROLLED CLINICAL TRIAL; DRUG EFFECT;

ADMINISTRATION, ORAL; ADULT; ANIMALS; BENZOXAZINES; BRAIN; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRONABINOL; ENDOCANNABINOIDS; FEMALE; GERMANY; HEALTHY VOLUNTEERS; HUMANS; MALE; MORPHOLINES; NAPHTHALENES; PSYCHOTROPIC DRUGS; RATS; RATS, INBRED LEW; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; SPINAL CORD; TIME FACTORS; UP-REGULATION;

EID: 84883797462     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3182984015     Document Type: Article

References (44)

1. Matsuda LA, Lolait SJ, Brownstein MJ, et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990;346(6284):561-564
2. Devane WA, Dysarz FA 3rd, Johnson MR, et al. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol. 1988;34(5):605-613
3. Rodriguez de Fonseca F, Del Arco I, Bermudez-Silva FJ, et al. The endocannabinoid system: Physiology and pharmacology. Alcohol Alcohol. 2005;40(1):2-14
4. Porter AC, Sauer JM, Knierman MD, et al. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther. 2002;301(3):1020-1024
5. Thabuis C, Tissot-Favre D, Bezelgues JB, et al. Biological functions and metabolism of oleoylethanolamide. Lipids. 2008;43(10):887-894
6. Godlewski G, Offertaler L, Wagner JA, et al. Receptors for acylethanolamidesVGPR55 and GPR119. Prostaglandins Other Lipid Mediat. 2009;89(3-4):105-111
7. Bequet F, Uzabiaga F, Desbazeille M, et al. CB1 receptor-mediated control of the release of endocannabinoids (as assessed by microdialysis coupled with LC/MS) in the rat hypothalamus. Eur J Neurosci. 2007;26(12):3458-3464
8. De Petrocellis L, Orlando P, Moriello AS, et al. Cannabinoid actions at TRPV channels: Effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation. Acta Physiol (Oxf) . 2012;204(2):255-266
9. Carroll CB, Zeissler ML, Hanemann CO, et al. Delta(9)-THC exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease. Neuropathol Appl Neurobiol. 2012;38:535-547
10. Sim-Selley LJ, Schechter NS, Rorrer WK, et al. Prolonged recovery rate of CB1 receptor adaptation after cessation of long-Term cannabinoid administration. Mol Pharmacol. 2006;70(3):986-996
11. Falenski KW, Thorpe AJ, Schlosburg JE, et al. FAAH-/-mice display differential tolerance, dependence, and cannabinoid receptor adaptation after delta 9-Tetrahydrocannabinol and anandamide administration. Neuropsychopharmacology. 2010;35(8):1775-1787
12. Piomelli D. The endogenous cannabinoid system and the treatment of marijuana dependence. Neuropharmacology. 2004;47(suppl 1): 359-367
13. Kelley BG, Thayer SA. Delta 9-Tetrahydrocannabinol antagonizes endocannabinoid modulation of synaptic transmission between hippocampal neurons in culture. Neuropharmacology. 2004;46(5):709-715
14. Mato S, Chevaleyre V, Robbe D, et al. A single in-vivo exposure to delta 9THC blocks endocannabinoid-mediated synaptic plasticity. Nat Neurosci. 2004;7(6):585-586
15. Walter C, Oertel BG, Felden L, et al. The effects of delta-9- Tetrahydrocannabinol on nasal chemosensitivity: A pharmacological fMRI study in healthy volunteers. Naunyn Schmiedebergs Arch Pharmacol. 2011;383(suppl 1):75
16. Hollister LE, Gillespie HK, Ohlsson A, et al. Do plasma concentrations of delta 9-Tetrahydrocannabinol reflect the degree of intoxication? J Clin Pharmacol. 1981;21(suppl 8-9):171S-177S
17. Bishay P, Schmidt H, Marian C, et al. R-flurbiprofen reduces neuropathic pain in rodents by restoring endogenous cannabinoids. PloS one. 2010;5(5):e10628
18. Lötsch J, Geisslinger G. Bedside-To-bench pharmacology: A complementary concept to translational pharmacology. Clin Pharmacol Ther. 2010;87(6):647-649
19. Heyman E, Gamelin FX, Goekint M, et al. Intense exercise increases circulating endocannabinoid and BDNF levels in humansVpossible implications for reward and depression. Psychoneuroendocrinology. 2011;37(6):844-851
20. Kofalvi A, Pereira MF, Rebola N, et al. Anandamide and NADA bi-directionally modulate presynaptic Ca2+ levels and transmitter release in the hippocampus. Br J Pharmacol. 2007;151(4):551-563
21. Gulyas AI, Cravatt BF, Bracey MH, et al. Segregation of two endocannabinoid-hydrolyzing enzymes into pre-And postsynaptic compartments in the rat hippocampus, cerebellum and amygdala. Eur J Neurosci. 2004;20(2):441-458
22. Puente N, Cui Y, Lassalle O, et al. Polymodal activation of the endocannabinoid system in the extended amygdala. Nat Neurosci. 2011;14(12):1542-1547
23. Gonthier MP, Hoareau L, Festy F, et al. Identification of endocannabinoids and related compounds in human fat cells. Obesity. 2007;15(4):837-845
24. Vlachou S, Stamatopoulou F, Nomikos GG, et al. Enhancement of endocannabinoid neurotransmission through CB1 cannabinoid receptors counteracts the reinforcing and psychostimulant effects of cocaine. Int J Neuropsychopharmacol. 2008;11(7):905-923
25. Rouzer CA, Marnett LJ. Endocannabinoid oxygenation by cyclooxygenases, lipoxygenases, and cytochromes P450: Cross-Talk between the eicosanoid and endocannabinoid signaling pathways. Chem Rev. 2011;111(10):5899-5921
26. Snider NT, Sikora MJ, Sridar C, et al. The endocannabinoid anandamide is a substrate for the human polymorphic cytochrome P450 2D6. J Pharmacol Exp Ther. 2008;327(2):538-545
27. Snider NT, Kornilov AM, Kent UM, et al. Anandamide metabolism by human liver and kidney microsomal cytochrome p450 enzymes to form hydroxyeicosatetraenoic and epoxyeicosatrienoic acid ethanolamides. J Pharmacol Exp Ther. 2007;321(2):590-597
28. Sridar C, Snider NT, Hollenberg PF. Anandamide oxidation by wild-Type and polymorphically expressed CYP2B6 and CYP2D6. Drug Metabol Dispos. 2011;39(5):782-788
29. Ruhaak LR, Felth J, Karlsson PC, et al. Evaluation of the cyclooxygenase inhibiting effects of six major cannabinoids isolated from Cannabis sativa. Biol Pharm Bull. 2011;34(5):774-778
30. Watanabe K, Matsunaga T, Yamamoto I, et al. Involvement of CYP2C in the metabolism of cannabinoids by human hepatic microsomes from an old woman. Biol Pharm Bull. 1995;18(8):1138-1141
31. Watanabe K, Yamaori S, Funahashi T, et al. Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes. Life Sci. 2007;80(15):1415-1419
32. Yamaori S, Ebisawa J, Okushima Y, et al. Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: Role of phenolic hydroxyl groups in the resorcinol moiety. Life Sci. 2011; 88(15-16):730-736
33. Wagner JA, Jarai Z, Batkai S, et al. Hemodynamic effects of cannabinoids: Coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors. Eur J Pharmacol. 2001; 423(2-3):203-210
34. Sachse-Seeboth C, Pfeil J, Sehrt D, et al. Interindividual variation in the pharmacokinetics of delta9-Tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9. Clin Pharmacol Ther. 2009;85(3):273-276
35. Rubino T, Parolaro D. Sexually dimorphic effects of cannabinoid compounds on emotion and cognition. Front Behav Neurosci. 2011;5:64
36. Viveros MP, Marco EM, Lopez-Gallardo M, et al. Framework for sex differences in adolescent neurobiology: A focus on cannabinoids. Neurosci Biobehav Rev. 2011;35(8):1740-1751
37. Gonzalez S, Bisogno T, Wenger T, et al. Sex steroid influence on cannabinoid CB(1) receptor mRNA and endocannabinoid levels in the anterior pituitary gland. Biochem Biophys Res Commun. 2000;270(1):260-266
38. Jackson AS, Stanforth PR, Gagnon J, et al. The effect of sex, age and race on estimating percentage body fat from body mass index: The Heritage Family Study. Int J Obes Relat Metab Disord. 2002;26(6):789-796
39. Maughan RJ, Watson JS, Weir J. Strength and cross-sectional area of human skeletal muscle. J Physiol. 1983;338:37-49
40. Schroeder C, Batkai S, Engeli S, et al. Circulating endocannabinoid concentrations during orthostatic stress. Clin Auton Res. 2009;19(6):343-346
41. Koethe D, Schreiber D, Giuffrida A, et al. Sleep deprivation increases oleoylethanolamide in human cerebrospinal fluid. J Neural Transm. 2009;116(3):301-305
42. Maccarrone M. Good news for CB1 receptors: Endogenous agonists are in the right place. Br J Pharmacol. 2008;153(2):179-181
43. Queckenberg C, Fuhr U. Influence of posture on pharmacokinetics. EurJ Clin Pharmacol. 2009;65(2):109-119
44. Varga K, Wagner JA, Bridgen DT, et al. Platelet-And macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J. 1998;12(11):1035-1044